Elan entered into agreement with Vernalis and Eisai to divest two of its potential neurological candidates. Vernalis reacquired its North American rights to Frova™ (frovatriptan), for treating migraine. The deal could be worth up to US$55 M to Elan.
Elan has also divested the North American, European and Mexican marketing rights to Eisai for Zonegran®, for treating epilepsy. The deal could be worth up to US$240 M to Elan.